Literature DB >> 23481450

Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience.

Ernesto Carlos González1, Frank Carvajal, Amarilys Frómeta, Ana Luisa Arteaga, Elisa María Castells, Tania Espinosa, Remigio Coto, Pedro Lucio Pérez, Yileidis Tejeda, Lesley Del Río, Mary Triny Segura, Pedro Almenares, René Robaina, José Luis Fernández.   

Abstract

BACKGROUND: Since 2005, a newborn screening program for congenital adrenal hyperplasia (CAH) by measuring 17-alpha-hydroxyprogesterone (17OHP) in dried blood spots was introduced in Cuba.
METHODS: The hormone was measured by the 17OHP Neonatal UMELISA method, in samples collected on the 5th day as average. Confirmatory test was performed to those neonates with 17OHP values above 55 nmol/l. Some perinatal factors that can influence on 17OHP levels were studied.
RESULTS: From January 2005 to December 2010, 621,303 newborns were screened and 39 CAH cases were detected. Coverage of the program reached 98%. The incidence of CAH in Cuba was 1:15,931, similar to that reported by other programs. A recall for suspected CAH was performed in 10,799 cases (1.74%). Therapy in classical CAH patients was started at the mean age of 22 days. 17OHP levels were significantly higher in newborns with lower birth-weight (BW) and/or gestational age (GA). In addition, 17OHP values were affected by the gender, twin status or mode of delivery.
CONCLUSIONS: In Cuba, the nationwide newborn screening program has allowed the early detection of CAH. The use of an optimized cut-off level for BW or GA could lead to a reduction in the percentage of recalled babies.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23481450     DOI: 10.1016/j.cca.2013.02.020

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  The influence of seasonality and manufacturer kit lot changes on 17α-hydroxyprogesterone measurements and referral rates of congenital adrenal hyperplasia in newborns.

Authors:  Melissa Pearce; Erin Dauerer; A Gregory DiRienzo; Michele Caggana; Norma P Tavakoli
Journal:  Eur J Pediatr       Date:  2016-11-29       Impact factor: 3.183

2.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

3.  Molecular Analysis of 21-Hydroxylase Deficiency Reveals Two Novel Severe Genotypes in Affected Newborns.

Authors:  Paola Concolino; Rosa Maria Paragliola
Journal:  Mol Diagn Ther       Date:  2021-03-12       Impact factor: 4.074

Review 4.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

5.  Molecular diagnosis of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Tania Mayvel Espinosa Reyes; Teresa Collazo Mesa; Paulina Arasely Lantigua Cruz; Adriana Agramonte Machado; Emma Domínguez Alonso; Henrik Falhammar
Journal:  BMC Endocr Disord       Date:  2020-11-09       Impact factor: 2.763

6.  Newborn screening for congenital adrenal hyperplasia in New York State.

Authors:  Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Rhonda Hamel; Breanne Maloney; Daniele-Marisa Stansfield; Emily C McGrath; Amanda Occhionero; Adam Gearhart; Michele Caggana; Norma P Tavakoli
Journal:  Mol Genet Metab Rep       Date:  2016-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.